表紙
市場調査レポート

おたふく風邪 : パイプライン分析

Mumps - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 271822
出版日 ページ情報 英文 44 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
おたふく風邪 : パイプライン分析 Mumps - Pipeline Review, H2 2016
出版日: 2016年07月20日 ページ情報: 英文 44 Pages
概要

おたふく風邪とはウイルス性の接触感染症で、唾液腺に痛みを伴う腫脹が生じます。病原ウイルスは、個人間の飛沫感染(鼻水など)や、ウイルス入り唾液のかかった物への直接接触などにより広がっていきます。主な症状として、発熱や顔面の痛み、頭痛、喉の痛み、こめかみや顎の腫れ、耳下腺の腫脹などが挙げられます。主な治療法としては、(症状緩和のための)鎮痛剤などがあります。

当レポートでは、世界各国でのおたふく風邪(流行性耳下腺炎)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

目次

イントロダクション

  • 分析範囲

おたふく風邪の概要

治療薬の開発

  • おたふく風邪向けパイプライン製品:概要
  • おたふく風邪向けパイプライン製品:比較分析

各企業で開発中のおたふく風邪治療薬

大学/研究機関で研究中のおたふく風邪治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

おたふく風邪治療薬:開発中の製品の一覧(企業別)

おたふく風邪治療薬:研究中の製品の一覧(大学/研究機関別)

おたふく風邪治療薬の開発に従事している企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • China National Pharmaceutical Group Corporation
  • GlaxoSmithKline Plc
  • Organic Vaccines
  • Prometheon Pharma, LLC
  • Sinovac Biotech Ltd.
  • Zydus Cadila Healthcare Limited

おたふく風邪:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • 麻疹・おたふく風邪・風疹(MMR)向け細胞療法
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • MMR+水痘ワクチン
  • MMR生ワクチン(新三種混合ワクチン)
  • 麻疹strain schwarz ・おたふく風邪strain RIT 4385・風疹strain wistar RA 27/3向けワクチン
  • おたふく風邪ワクチン

おたふく風邪治療薬:パイプライン製品の最新動向

おたふく風邪治療薬:開発が休止状態の製品

おたふく風邪関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8243IDB

Summary

Global Markets Direct's, 'Mumps - Pipeline Review, H2 2016', provides an overview of the Mumps pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mumps, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mumps and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mumps
  • The report reviews pipeline therapeutics for Mumps by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Mumps therapeutics and enlists all their major and minor projects
  • The report assesses Mumps therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Mumps

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Mumps
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mumps pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mumps Overview
  • Therapeutics Development
    • Pipeline Products for Mumps - Overview
    • Pipeline Products for Mumps - Comparative Analysis
  • Mumps - Therapeutics under Development by Companies
  • Mumps - Therapeutics under Investigation by Universities/Institutes
  • Mumps - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Mumps - Products under Development by Companies
  • Mumps - Products under Investigation by Universities/Institutes
  • Mumps - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co., Ltd
    • Beijing Tiantan Biological Products Co., Ltd.
    • China National Pharmaceutical Group Corporation
    • Daiichi Sankyo Company, Limited
    • GlaxoSmithKline Plc
    • Prometheon Pharma, LLC
    • Sinovac Biotech Ltd.
    • Zydus Cadila Healthcare Limited
  • Mumps - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (measles + mumps + rubella + varicella) (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • measles + mumps + rubella + varicella vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mumps vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mumps vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Mumps - Dormant Projects
  • Mumps - Product Development Milestones
    • Featured News & Press Releases
      • Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Mumps, H2 2016
  • Number of Products under Development for Mumps - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Mumps - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
  • Mumps - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016
  • Mumps - Pipeline by China National Pharmaceutical Group Corporation, H2 2016
  • Mumps - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Mumps - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Mumps - Pipeline by Prometheon Pharma, LLC, H2 2016
  • Mumps - Pipeline by Sinovac Biotech Ltd., H2 2016
  • Mumps - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Mumps - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Mumps, H2 2016
  • Number of Products under Development for Mumps - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top